US5096926A - Injectable formulations containing the sodium salt of naproxen - Google Patents

Injectable formulations containing the sodium salt of naproxen Download PDF

Info

Publication number
US5096926A
US5096926A US07/622,925 US62292590A US5096926A US 5096926 A US5096926 A US 5096926A US 62292590 A US62292590 A US 62292590A US 5096926 A US5096926 A US 5096926A
Authority
US
United States
Prior art keywords
clear clear
colorless colorless
naproxen
sodium salt
stabilizing agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US07/622,925
Other languages
English (en)
Inventor
Roberta Fiorini
Egidio Marchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alfa Wasserman SpA
Original Assignee
Alfa Wasserman SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfa Wasserman SpA filed Critical Alfa Wasserman SpA
Assigned to ALFA WASSERMANN S.P.A., A CORP. OF ITALY reassignment ALFA WASSERMANN S.P.A., A CORP. OF ITALY ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: FIORINI, ROBERTA, MARCHI, EGIDIO
Application granted granted Critical
Publication of US5096926A publication Critical patent/US5096926A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D65/00—Wrappers or flexible covers; Packaging materials of special type or form
    • B65D65/02—Wrappers or flexible covers
    • B65D65/16—Wrappers or flexible covers with provision for excluding or admitting light
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D75/00—Packages comprising articles or materials partially or wholly enclosed in strips, sheets, blanks, tubes, or webs of flexible sheet material, e.g. in folded wrappers
    • B65D75/28—Articles or materials wholly enclosed in composite wrappers, i.e. wrappers formed by associating or interconnecting two or more sheets or blanks
    • B65D75/30—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding
    • B65D75/32—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
    • B65D75/325—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet being recessed, and the other being a flat not- rigid sheet, e.g. puncturable or peelable foil
    • B65D75/327—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet being recessed, and the other being a flat not- rigid sheet, e.g. puncturable or peelable foil and forming several compartments

Definitions

  • the method of parenteral administration is known to be useful in helping the absorption of many drugs and, among them, also of the non-steroidal anti-inflammatory drugs.
  • the sodium salt of naproxen among these, a drug universally known for its valued analgesic, antipyretic and anti-inflammatory activities, has a remarkable importance.
  • the object of the present invention consists in finding a system to make stable for a long period of time aqueous solutions containing the sodium salt of the naproxen also in the presence of unfavourable conditions of heat and light.
  • Aqueous injectable pharmaceutical formulations containing therapeutically effective amounts of naproxen sodium salt, a drug endowed with anti-inflammatory, analgesic and antipyretic activity, together with stabilizing agents and polyhydroxylic alcohols and, optionally, excipients like, for instance, local anaesthetics like the lidocaine base or lidocaine salts, preferably the hydrochloride, or mixtures thereof, are the object of the present invention.
  • a type of packaging where the containers of the vials or of the medicine-bottles are boxes of polystyrene or of an equivalent material, like, for instance, polyvinylchloride, covered by films that absorb the light radiations, is a further object of the present invention, equally with the scope to keep stable during the time the injectable solutions containing the sodium salt of the naproxen.
  • the realization of the invention consists of adding an amount of stabilizing agents comprised between 0.25% and 5% by weight and an amount of polyhydroxylic alcohols comprised between 5% and 50% in weight and, optionally, some excipients like, for instance, local anaesthetics like lidocaine base or lidocaine salts, preferably the hydrochloride, or mixtures thereof, to an aqueous solution containing from 3% to 15% in weight of the sodium salt of the naproxen and in packaging the vials or the medicine-bottles in a box covered by a film that absorbs the light radiations.
  • an amount of stabilizing agents comprised between 0.25% and 5% by weight and an amount of polyhydroxylic alcohols comprised between 5% and 50% in weight and, optionally, some excipients like, for instance, local anaesthetics like lidocaine base or lidocaine salts, preferably the hydrochloride, or mixtures thereof, to an aqueous solution containing from 3% to 15% in weight of the sodium
  • the prefered dosage of the sodium salt of the naproxen is comprised between 200 and 1000 mg for each vial or medicine-bottle, the amount of the stabilizing agents between 10 and 300 mg and the amount of polyhydroxylic alcohols between 200 and 2000 mg.
  • N-acetyl-L-cysteine, cysteine, cysteamine, cystamine, glutathione, imidazole and mixtures thereof are preferred among the stabilizing agents.
  • polyhydroxylic alcohols are suitable in order to obtain the desired results within the scope of the invention and propylene glycol, sorbitol, mannitol, xylitol, glycerol, inositol and mixtures thereof are the preferred ones.
  • the container of vials or medicine-bottles is made of a box of polystyrene or of an equivalent material, like for instance polyvinylchloride, in the shape of a parallelepiped (1) containing in its interior a series of division walls (2) which mark the limits of the lodgings (3) for the single vials or medicine-bottles, covered by a film (4) which absorbs the light radiations.
  • Both the containers and the vials or the medicine-bottles can be of various dimensions; generally the number of the lodgings is comprised between 2 and 12 and the content of each single vial or medicine-bottle is comprised between 1 ml and 10 ml.
  • the packaging contains 6 vials having a volume of 4 ml.
  • the preparation of the injectable solutions takes place by dissolving the stabilizing agents in about 2/3 of the foreseen amount of water for injectable preparations and then by bringing the pH of the solution to a value comprised between 7.5 and 9.5 by means of a 10% (w/w) aqueous solution of sodium hydroxide or of 1N hydrochloric acid.
  • the polyhydroxylic alcohol, the sodium salt of the naproxen and possible excipients like local anaesthetics like lidocaine base or salts of lidocaine, preferably the hydrochloride, or mixtures thereof, are added afterwards.
  • the injectable solution is brought to the end desired volume, by contemporaneously checking the value of the pH by means of a possible addition of a 10% (w/w) aqueous solution of sodium hydroxide or of 1N hydrochloric acid, by adding water for injectable preparations and lastly it is sterilely filtered and put into the vials or the medicine-bottles in aseptic ambient.
  • the whole process for the preparation of the injectable solutions comprised the final filling of vials or of medicine-bottles, is carried out under nitrogen atmosphere.
  • the first stability test is a thermostability test: the samples described in examples from 1 to 8 and the two comparison samples have been stored in a thermostatic stove at the temperature of 60° C. in the dark.
  • the second stability test is a photostability test: the samples described in examples from 1 to 10 and the two comparison samples have been exposed, in a suitable chamber, to the natural light, at a temperature ranging between about 20° C. and about 45° C.
  • the investigated parameters are those that the experience showed to be representative of the likely reactions of degradation, exactly the clearness and the color.
  • the solution because of the phenomena of degradation, goes from colorless to colored, the color darkening with the progress of the processes of degradation and subsequently it loses its clearness, it becomes opaque and, lastly, some solid substance precipitates.
  • JB JAUNE BRUNATRE (YELLOW BROWN)
  • the number of the color is decreasing at the increase of the intensity, i.e. number 1 represents the most intense coloring.
  • N-acetyl-L-cysteine 50 Grams of N-acetyl-L-cysteine are dissolved, under nitrogen atmosphere, in 2600 ml of water for injectable preparations and then the value of the pH is brought to 8.5 by means of a 10% (w/v) aqueous solution of sodium hydroxide.
  • the solution is then brought to the volume of 4000 ml by adding water for injectable preparations while contemporaneously keeping the value of the pH at 8.5 by means of a possible addition of a 10% (w/v) aqueous solution of sodium hydroxide.
  • the so obtained solution is sterilely filtered and lastly used to fill, in aseptic ambient under nitrogen atmosphere, 1000 vials having a volume of 4 ml which are packaged in containers of a shape analogous to that shown in FIGS. 1, 2 and 3 covered by a film of polythene of dark green color.
  • the preparation according to example 1 is repeated, by packaging in containers covered by a film of polythene of dark red color.
  • the preparation according to example 1 is repeated, by packaging in containers covered by a film of polythene of amber color.
  • the preparation according to example 1 is repeated, by packaging in containers covered by a film of aluminium.
  • the preparation according to example 1 is repeated, by packaging in containers covered by a film of polystyrene.
  • the preparation is carried out exactly as in example 1 with the only difference that 100 g of imidazole are used as stabilizing agent instead of 50 g of N-acetyl-L-cysteine.
  • the pH is kept at the value of 8.5 by adding a sterile aqueous solution of 1N hydrochloric acid.
  • the preparation is carried out exactly as in example 1 with the only difference that 100 g of glutathione are used as stabilizing agent instead of 50 g of N-acetyl-L-cysteine.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Composite Materials (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US07/622,925 1990-04-17 1990-12-06 Injectable formulations containing the sodium salt of naproxen Expired - Fee Related US5096926A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT3452A/90 1990-04-17
IT00345290A IT1242642B (it) 1990-04-17 1990-04-17 Formulazioni iniettabili contenenti naproxen sale sodico.

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US07/679,113 Division US5128373A (en) 1990-04-17 1991-04-02 Packages containing injectable formulations of the sodium salt of naproxen

Publications (1)

Publication Number Publication Date
US5096926A true US5096926A (en) 1992-03-17

Family

ID=11107641

Family Applications (2)

Application Number Title Priority Date Filing Date
US07/622,925 Expired - Fee Related US5096926A (en) 1990-04-17 1990-12-06 Injectable formulations containing the sodium salt of naproxen
US07/679,113 Expired - Fee Related US5128373A (en) 1990-04-17 1991-04-02 Packages containing injectable formulations of the sodium salt of naproxen

Family Applications After (1)

Application Number Title Priority Date Filing Date
US07/679,113 Expired - Fee Related US5128373A (en) 1990-04-17 1991-04-02 Packages containing injectable formulations of the sodium salt of naproxen

Country Status (11)

Country Link
US (2) US5096926A (de)
EP (1) EP0463228A3 (de)
JP (1) JPH045230A (de)
KR (1) KR0180230B1 (de)
AU (1) AU627639B2 (de)
CA (1) CA2031994A1 (de)
IE (1) IE904291A1 (de)
IT (1) IT1242642B (de)
NZ (1) NZ236356A (de)
PT (1) PT96263A (de)
ZA (1) ZA909949B (de)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326230A (en) * 1991-10-25 1994-07-05 Mannesmann Rexroth Gmbh Closed loop control circuit for variable hydraulic pump
US5700653A (en) * 1994-05-06 1997-12-23 Beckman Instruments, Inc. Liquid stable thiol activator
WO1998046235A1 (de) * 1997-04-15 1998-10-22 Bayer Aktiengesellschaft Analgetika-kombination
US5834479A (en) * 1993-03-05 1998-11-10 Mayer; David J. Method and composition for alleviating pain
US5904935A (en) * 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
US5916583A (en) * 1992-07-09 1999-06-29 Astra Aktiebolag Precipitation of one or more active compounds in situ
US6197787B1 (en) 1997-03-03 2001-03-06 Sanofi-Synthelabo Pharmaceutical formulations containing poorly soluble drug substances
US20040068007A1 (en) * 2002-10-02 2004-04-08 Fang-Yu Lee Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same
US20060020035A1 (en) * 2004-03-11 2006-01-26 Oregon Health & Science University Bone marrow protection with N-acetyl-L-cysteine
US20100279993A1 (en) * 2002-12-30 2010-11-04 Mark Tawa Pharmaceutical Propylene Glycol Solvate Compositions
US8362062B2 (en) 2002-02-15 2013-01-29 Mcneil-Ppc, Inc. Pharmaceutical compositions with improved dissolution

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153225A (en) * 1998-08-13 2000-11-28 Elan Pharma International Limited Injectable formulations of nanoparticulate naproxen
US6552082B2 (en) * 2000-06-29 2003-04-22 Ono Pharmaceutical Co., Ltd. Solution of N-[o-(p-pivaloyloxybenzenesulfonylamino)benzoyl] glycine monosodium salt tetra-hydrate and drug product thereof
CN105314212B (zh) * 2014-07-07 2018-03-02 河南科技大学第一附属医院 一种药品切割存放盒
WO2023043207A1 (ko) * 2021-09-15 2023-03-23 구주제약주식회사 안정성이 향상된 프로피오닉산 계열 약물 및 안정화제를 포함하는 약학 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309421A (en) * 1979-04-11 1982-01-05 A. Nattermann & Cie. Gmbh Stabilized parenterally administrable solutions
US4593044A (en) * 1983-08-05 1986-06-03 Merckle Gmbh Injectable solution for the treatment of inflammations
US4704406A (en) * 1985-06-24 1987-11-03 Klinge Pharma Gmbh Sprayable pharmaceutical composition for topical use
US4769236A (en) * 1982-04-19 1988-09-06 Elan Corporation, Plc Medicaments with a high degree of solubility and method for their production

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3207302A (en) * 1962-07-10 1965-09-21 American Home Prod Tamper-proof container for hypodermic syringes
US3707227A (en) * 1970-07-06 1972-12-26 Owens Illinois Inc Tray package for tubes
US3873718A (en) * 1973-03-29 1975-03-25 Syntex Corp Method for delaying the onset of, or postponing, parturition
US4150744A (en) * 1976-02-27 1979-04-24 Smith & Nephew Pharmaceuticals Ltd. Packaging
AU546483B2 (en) * 1982-10-08 1985-09-05 Terumo Kabushiki Kaisha Evacuated blood collecting device
FR2545066B1 (fr) * 1983-04-27 1986-01-24 Levy Claude Emballage, notamment pour le transport et l'expedition de produits, biologiques, par exemple
DE3446873A1 (de) * 1984-12-21 1986-07-10 Merckle Gmbh Fluessige diclofenac-zubereitungen
US4799590A (en) * 1987-02-02 1989-01-24 Furman Theodore J Package and method of packaging

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309421A (en) * 1979-04-11 1982-01-05 A. Nattermann & Cie. Gmbh Stabilized parenterally administrable solutions
US4769236A (en) * 1982-04-19 1988-09-06 Elan Corporation, Plc Medicaments with a high degree of solubility and method for their production
US4593044A (en) * 1983-08-05 1986-06-03 Merckle Gmbh Injectable solution for the treatment of inflammations
US4593044B1 (de) * 1983-08-05 1988-06-21
US4704406A (en) * 1985-06-24 1987-11-03 Klinge Pharma Gmbh Sprayable pharmaceutical composition for topical use

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326230A (en) * 1991-10-25 1994-07-05 Mannesmann Rexroth Gmbh Closed loop control circuit for variable hydraulic pump
US5916583A (en) * 1992-07-09 1999-06-29 Astra Aktiebolag Precipitation of one or more active compounds in situ
US5834479A (en) * 1993-03-05 1998-11-10 Mayer; David J. Method and composition for alleviating pain
US5700653A (en) * 1994-05-06 1997-12-23 Beckman Instruments, Inc. Liquid stable thiol activator
US5904935A (en) * 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
US5972370A (en) * 1995-06-07 1999-10-26 Alza Corporation Peptide/protein suspending formulations
US6197787B1 (en) 1997-03-03 2001-03-06 Sanofi-Synthelabo Pharmaceutical formulations containing poorly soluble drug substances
WO1998046235A1 (de) * 1997-04-15 1998-10-22 Bayer Aktiengesellschaft Analgetika-kombination
US6929805B2 (en) 1997-04-15 2005-08-16 Bayer Aktiengesellschaft Analgesic combination
US8362062B2 (en) 2002-02-15 2013-01-29 Mcneil-Ppc, Inc. Pharmaceutical compositions with improved dissolution
US20040068007A1 (en) * 2002-10-02 2004-04-08 Fang-Yu Lee Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same
US7166641B2 (en) * 2002-10-02 2007-01-23 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same
US20100279993A1 (en) * 2002-12-30 2010-11-04 Mark Tawa Pharmaceutical Propylene Glycol Solvate Compositions
US8183290B2 (en) * 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US8492423B2 (en) 2002-12-30 2013-07-23 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US20060020035A1 (en) * 2004-03-11 2006-01-26 Oregon Health & Science University Bone marrow protection with N-acetyl-L-cysteine

Also Published As

Publication number Publication date
ZA909949B (en) 1991-10-30
KR910021240A (ko) 1991-12-20
AU6769190A (en) 1991-10-24
US5128373A (en) 1992-07-07
JPH045230A (ja) 1992-01-09
KR0180230B1 (ko) 1999-03-20
PT96263A (pt) 1991-10-31
IE904291A1 (en) 1991-10-23
IT1242642B (it) 1994-05-16
CA2031994A1 (en) 1991-10-18
IT9003452A1 (it) 1991-10-18
EP0463228A2 (de) 1992-01-02
NZ236356A (en) 1993-01-27
AU627639B2 (en) 1992-08-27
IT9003452A0 (it) 1990-04-17
EP0463228A3 (en) 1992-03-25

Similar Documents

Publication Publication Date Title
US5096926A (en) Injectable formulations containing the sodium salt of naproxen
AU658011B2 (en) Improved lyophilized ifosfamide compositions
PL187170B1 (pl) Kompozycja farmaceutyczna zawierająca sole alkiloamonowe kwasów 2-arylopropionowych do pozajelitowego stosowania i sposób otrzymywania kompozycji
Thoma et al. Photostabilization of drugs in dosage forms without protection from packaging materials
KR20020081293A (ko) 페메트렉시드를 모노티오글리세롤 ｌ-시스테인 또는티오글리콜산과 함께 포함하는 제약 조성물
Lachman Physical and chemical stability testing of tablet dosage forms
EP0319964B1 (de) Filmbildende antifungale Zubereitung
WO2020158894A1 (ja) ポリスルフィド化合物を含有する組成物
AU1350799A (en) Minoxidil-containing liquid composition
ES2198424T3 (es) Soluciones inyectables listas para el empleo que contienen doxorrubicina.
JPS5857322A (ja) 光不安定な医薬物質の安定化方法
Templeton et al. Implications of photostability on the manufacturing, packaging, storage, and testing
JPH03130226A (ja) １つより多いエチレンイミン基を有する抗新生物性化合物用の安定な製薬学的配合及び方法
US11707434B2 (en) Method for preparing organic solvent-free lyophilized cyclophosphamide
DK164535B (da) Etopsidpraeparat til oral administrering
WO2021195256A1 (en) Pharmaceutical preparation
EP0051962B1 (de) Pharmazeutische Zusammensetzung mit Gehalt an 4-Carbamoyl-imidazolium-5-olat
KR890000905B1 (ko) 비경구용 액제
CA1333774C (en) Soft capsular preparation of sodium picosulfate
Siegel et al. Tablets of pyrilamine resin adsorbate with aspirin and vitamin C
KR100399483B1 (ko) 플로로글루시놀을 유효성분으로 함유하는 신규 진경액제
IL270035B2 (en) A method for preparing a composition with a low amount of dissolved oxygen, containing acetaminophen, and optionally one or more nasids and a composition obtained therefrom
US20230364093A1 (en) Pharmaceutical composition containing palbociclib and letrozole
Zhou Cyclosporine A: Solubilization, solid dispersion and solid-state transformation
JPH0349828B2 (de)

Legal Events

Date Code Title Description
AS Assignment

Owner name: ALFA WASSERMANN S.P.A., CONTRADA SANT'EMIDIO, 6502

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:FIORINI, ROBERTA;MARCHI, EGIDIO;REEL/FRAME:005530/0686

Effective date: 19901119

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
FP Lapsed due to failure to pay maintenance fee

Effective date: 19960320

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362